Yet, neither of the drugs is studied in patients based on stratification dependent on the presence of mutant TP53. Only one trial reported outcomes for vorinostat and decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome, but did not report the status of TP53 [101]. This evidence concerns the gene TP53 and acute myeloid leukemia.